SAN FRANCISCO, Dec. 20, 2018 /PRNewswire-PRWeb/ -- uBiome, the leader in microbial genomics, announces the addition of Dr. Jana Jandova, PhD, Assistant Scientific Investigator with the Department of Otolaryngology - Head & Neck Surgery at the University of Arizona, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Jandova will bring to uBiome expertise in the role of microbiome composition in chronic sinus disease. The appointment will help uBiome continue its advancement in human microbiome research.
"Dr. Jandova's extensive experience and broad scope of knowledge of chronic sinus disease, colon cancer, and Human Papillomavirus is invaluable," Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. "We are fortunate to have her as a member of our Scientific Advisory Board."
Dr. Jandova received her PhD in Medical Pharmacology from Palacky University in the Czech Republic. She underwent her post-doctoral training at the University of Arizona Cancer Center under the mentorship of Dr. Watts and Dr. Sligh. She has experience researching colorectal cancer, stem cells, oncogenic Human Papillomavirus, and non-melanoma skin cancer. Dr. Jandova joined the Chang Lab at the University of Arizona in 2018, and her current research focuses on how underlying genetic factors, viral infections, and microbiome composition all interact to drive the development of chronic sinus disease. She is the Assistant Scientific Investigator at the Departments of Otolaryngology and Surgery within the Surgical Oncology Section.
About joining uBiome's Scientific Advisory Board, Dr. Jandova said, "The 'big' world of human microbiome is extremely fascinating to me, simply because the genes in our microbiome outnumber the genes in our genome by about 100 times. I am particularly interested in gut microbiome in young patients with sporadic colorectal cancer. Another area of interest for me is to look at the changes in sinonasal microbiome in patients with chronic rhinosinusitis, especially after rhinovirus infection."
In addition to Dr. Jandova, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company's Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children's Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
_____ About uBiome Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.
SOURCE Ubiome
Advertisement
"Dr. Jandova's extensive experience and broad scope of knowledge of chronic sinus disease, colon cancer, and Human Papillomavirus is invaluable," Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. "We are fortunate to have her as a member of our Scientific Advisory Board."
Advertisement
Dr. Jandova received her PhD in Medical Pharmacology from Palacky University in the Czech Republic. She underwent her post-doctoral training at the University of Arizona Cancer Center under the mentorship of Dr. Watts and Dr. Sligh. She has experience researching colorectal cancer, stem cells, oncogenic Human Papillomavirus, and non-melanoma skin cancer. Dr. Jandova joined the Chang Lab at the University of Arizona in 2018, and her current research focuses on how underlying genetic factors, viral infections, and microbiome composition all interact to drive the development of chronic sinus disease. She is the Assistant Scientific Investigator at the Departments of Otolaryngology and Surgery within the Surgical Oncology Section.
About joining uBiome's Scientific Advisory Board, Dr. Jandova said, "The 'big' world of human microbiome is extremely fascinating to me, simply because the genes in our microbiome outnumber the genes in our genome by about 100 times. I am particularly interested in gut microbiome in young patients with sporadic colorectal cancer. Another area of interest for me is to look at the changes in sinonasal microbiome in patients with chronic rhinosinusitis, especially after rhinovirus infection."
In addition to Dr. Jandova, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company's Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children's Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
_____ About uBiome Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.
SOURCE Ubiome
